摘要
目的探讨血清神经元特异性稀醇化酶(NSE)对小细胞肺癌鉴别诊断和判断预后中的临床意义。方法采用酶联免疫吸附试验(ELISA)法测量不同组织学分类的130例肺癌患者化疗前后血清中NSE水平及阳性率,同时随访化疗后小细胞肺癌患者的平均生存时间,进行统计学分析。结果血清中NSE数值在小细胞肺癌患者组中最高,与非小细胞肺癌组及健康对照组相比较差异有统计学意义(P<0.05),NSE的阳性率在小细胞肺癌组中为78.8%,非小细胞肺癌组为23.4%,与小细胞肺癌组相比较差异有统计学意义(P<0.05)。此外小细胞肺癌患者血清NSE>30μg/L者平均生存期缩短,与NSE≤30μg/L者相比较差异有统计学意义(P<0.05);尤其以化疗后NSE>30μg/L者明显(P<0.01)。结论血清NSE可作为对肺癌早期诊断、鉴别诊断及判断预后的较好参照指标。
Objective To investigate the diagnostic and prognostic value of neuron specific enolase（NSE）levels in small cell lung cancer patients.Methods NSE were measured by ELISA from 130 cases of different types of lung cancer patients,then mean survival time of small cell lung cancer patients were estimated in statistics.Results NSE and Its positive incidence in the group of small cell lung cancer is significantly higher than the other groups（P0.05）;Furthermore,the patients whose NSE under 30 μg/L have a better prognosis in the group of small cell lung cancer,especially in patients who still got a NSE Under 30 μg/L after chemotherapy（P0.01）.Conclusion NSE is helpful for differentiating diagnosis of lung cancer and could be a sensitive prognostic index in small cell lung cancer especially.
出处
《检验医学与临床》
CAS
2011年第4期419-420,共2页
Laboratory Medicine and Clinic
